Several clinical investigations have highlighted the association between ABCB1/ABCG2 polymorphisms and the efficacy of imatinib in both CML and GIST [10]. The gene discussed is ABCB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.